Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis‐Requiring Severe Renal Impairment
Early VGPR and hemodialysis independence translated to improved survival, providing a benchmark for future comparison as anti-CD38 monoclonal antibodies enter first line therapy.
Authors
- Anca Prica
- Harjot Vohra
- Esther Masih‐Khan (ORCID: https://orcid.org/0000-0002-7271-0680)
- Guido Lancman (ORCID: https://orcid.org/0000-0002-9775-7127)
- Rodger Edwin Tiedemann (ORCID: https://orcid.org/0000-0003-1743-8810)
- Sita Bhella (ORCID: https://orcid.org/0009-0005-9553-4340)
- Suzanne Trudel (ORCID: https://orcid.org/0000-0001-7952-6352)
- Rintu Sharma (ORCID: https://orcid.org/0000-0002-3407-1355)
- Jing Yang (ORCID: https://orcid.org/0009-0004-6493-5638)
- Vishal Kukreti
- Eshetu G. Atenafu
- Christine Chen
- A. Keith Stewart
- Donna Reece
Institutions
- University Health Network (CA)
- University of Auckland (NZ)
- Princess Margaret Cancer Centre (CA)
Publication Details
- Journal
- European Journal Of Haematology
- Published
- 2026-01-14
- DOI
- https://doi.org/10.1111/ejh.70116
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00